The Root of Failed Recruitment, Recursion's AI/ML Outlook and More
Clinical Leader
A resource and forum to investigate and resolve the common struggles related to running effective clinical trials.
Welcome to the Clinical Trial Insights newsletter, featuring strategic insights and expert opinions on designing and running clinical trials. Each edition covers the latest trending articles on?ClinicalLeader.com.
In this week's issue, we'll review the importance of recognizing patients' needs to avoid failed recruitment, Recursion 's outlook on AI/ML in drug discovery and development, how to cultivate a diverse and well-prepared clinical research workforce, best practices for site selection and study startup, and other popular insights.
If you like what you're seeing in our condensed LinkedIn editions, subscribe to our daily newsletter for full access to exclusive articles, webinars, e-books, and more!?Subscribe Now →?
TOP 5 READS OF THE PAST WEEK
If you work in clinical research long enough, certain data points are slowly carved into your frontal lobe. Like the fact that 86% of clinical trials fail to meet timelines?and that patient recruitment is the most common cause of delay. Patient advocates and consultants Richie Kahn and Jennifer McNary say failed recruitment efforts often have to do with a fundamental mismatch between how a trial is designed and patients’ actual wants and needs.
"TechBio" company Recursion has entered agreements to acquire AI/ML company Cyclica (acquired by Recursion, Nasdaq: RXRX) for $40 million and Valence Labs for $47.5 million. To learn about the acquisitions and the future of AI/ML in drug discovery and development, we caught up with Recursion’s CEO Chris Gibson .
In a DIA webinar following up on a forum convened by the ACRP - Association of Clinical Research Professionals , and a related?White Paper, Susan P. Landis , ACRP's executive director, explores the workforce shortage in clinical research, its root causes, and ways to “turn barriers into bridges.”
领英推荐
Site management organizations account for 10-20% of total clinical trial patient volume, but they're use among sponsors is on the rise. Explore key trends shaping the SMO landscape and value proposition, what implications these trends have for trial sponsors, and how sponsors can adapt to these evolving conditions
The study startup process is a critical point in research, and oftentimes, can make or break a study’s success. Advarra 's Meghan Hosely reviews how addressing study startup challenges head-on and fostering effective teamwork can help researchers optimize process efforts, setting a solid foundation for the research endeavor's overall success.
MORE TO EXPLORE
Clinical Leader is an online community serving professionals in the clinical research space. We share insights and best practices — from industry experts — to help sponsors and CROs tackle the biggest challenges they face in designing and running clinical trials.
To get the most out of our offerings,?join the Clinical Leader community.